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A Pilot Cost-Effectiveness Analysis of Treatments
in Newly Diagnosed High-Grade Gliomas: The
Example of 5-Aminolevulinic Acid Compared With
White-Light Surgery
BACKGROUND: High-grade gliomas are aggressive, incurable tumors characterized by
extensive diffuse invasion of the normal brain parenchyma. Novel therapies at best prolong
survival; their costs are formidable and benefit is marginal. Economic restrictions thus require
knowledge of the cost-effectiveness of treatments. Here, we show the cost-effectiveness of
enhanced resections in malignant glioma surgery using a well-characterized tool for intra-
operative tumor visualization, 5-aminolevulinic acid (5-ALA).
OBJECTIVE: To evaluate the cost-effectiveness of 5-ALA fluorescence-guided neuro-
surgery compared with white-light surgery in adult patients with newly diagnosed
high-grade glioma, adopting the perspective of the Portuguese National Health Service.
METHODS: We used a Markov model (cohort simulation). Transition probabilities were
estimated with the use of data from 1 randomized clinical trial and 1 noninterventional
prospective study. Utility values and resource use were obtained from published litera-
ture and expert opinion. Unit costs were taken from official Portuguese reimbursement
lists (2012 values). The health outcomes considered were quality-adjusted life-years, life-
years, and progression-free life-years. Extensive 1-way and probabilistic sensitivity anal-
yses were performed.
RESULTS: The incremental cost-effectiveness ratios are below €10 000 in all evaluated
outcomes, being around €9100 per quality-adjusted life-year gained, €6700 per life-year
gained, and €8800 per progression-free life-year gained. The probability of 5-ALA
fluorescence-guided surgery cost-effectiveness at a threshold of €20000 is 96.0% for
quality-adjusted life-year, 99.6% for life-year, and 98.8% for progression-free life-year.
CONCLUSION: 5-ALA fluorescence-guided surgery appears to be cost-effective in
newly diagnosed high-grade gliomas compared with white-light surgery. This example
demonstrates cost-effectiveness analyses for malignant glioma surgery to be feasible on
the basis of existing data.
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H
igh-grade gliomas (World Health Orga-
nization grade III/IV) are the most com-
mon brain tumors in adults.1 In Europe,
the standardized incidence rate of high-grade
gliomas is 3.13/100000 inhabitants per year.
The incidence is higher in adults, with a peak
.65 years of age.2 Glioblastoma is the most
common malignant tumor, accounting for 46%
of all primary malignant brain tumors.3 High-
grade gliomas are incurable tumors derived from
glial cells characterized by extensive diffuse
invasion of the normal brain parenchyma. The
factors for poor prognosis are older age, glio-
blastoma histology, poor performance status,
and unresectable tumor.2,4
Standard treatment for newly diagnosed pa-
tients comprises microsurgical resection followed
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FIGURE 1. Influence diagram. 5-ALA, 5-aminolevulinic acid; PDeathCR, probability of death for patients with complete
resection (time dependent); PDeathPR, probability of death in patients with partial resection (time dependent); Surg2CR_5ALA,
probability of complete resection with 5-ALA surgery; StaCR2Pro, probability of progression in patients with complete resection;
Surg2CRstand, probability of complete resection with white-light surgery; StaPR2Pro, probability of progression in patients with
partial resection; Surg2D, probability of death within 4 weeks of initial debulking surgery; Surg2PR_5ALA, probability of partial
resection with 5-ALA surgery; Surg2PRstand, probability of partial resection with white-light surgery.
TABLE 1. Input Values and Study Parametersa
Parameter Value (95% CI) Probability Distribution Reference
Transition probabilities
Surg2D 0.00375 Expert panel
Surg2CR_5ALA 0.65 b Stummer et al14
Surg2CRstand 0.36
Surg2PR_5ALA 0.35 b Stummer et al14
Surg2PRstand 0.64
StaCR2Pro 0.0197b Log normal Stummer et al13
StaPR2Pro 0.0086b
PDeathCR Time dependentc Log normal Stummer et al13
PDeathPR
Utilities
Surgery (week 1) and postoperative period (week 2-4) 0.8870 (0.845-0.929) b Rogers et al17
Stable disease, RT 0.8239 (0.425-0.995) b Garside et al16
Stable disease, RT 1 TMZ 0.7426 (0.175-0.980)
Stable disease, TMZadj 0.7331 (0.175-0.990)
Stable disease, no active treatment 0.8872 (0.525-1.000)
Progressive disease (first week)d 0.7314 (0.125-0.995) b Garside et al16
aCI, confidence interval; 5-ALA, 5-aminolevulinic acid; PDeathCR, probability of death for patients with complete resection (time dependent); PDeathPR, probability of death
in patients with partial resection (time dependent); RT, radiotherapy; RT1 TMZ, concomitant chemoradiotherapy with temozolomide; StaCR2Pro, probability of progression in
patients with complete resection; StaPR2Pro, probability of progression in patients with partial resection; Surg2CR_5ALA, probability of complete resection with 5-ALA surgery;
Surg2CRstand, probability of complete resection with white-light surgery; Surg2D, probability of death within 4 weeks of initial debulking surgery; Surg2PR_5ALA, probability
of partial resection with 5-ALA surgery; Surg2PRstand, probability of partial resection with white-light surgery; TMZadj, adjuvant treatment with temozolomide.
bExponential model.
cWeibull model.
dAfter first week in progression, a decrement rate of 0.5% was applied to utility scores.
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by concomitant temozolomide radiochemotherapy (the Stupp
regimen) or radiotherapy for anaplastic astrocytoma and oligoden-
droglioma subtypes.5,6
Extent of resection is an important prognostic factor for survival
in patients undergoing initial resection,7-11 including fit elderly
patients to whom aggressive surgery is not commonly offered.12
Even though 1 study has shown a positive continuous correlation
between extent of resection and survival,7 the majority of studies
suggest that an extent of resection of at least 98% is necessary to
affect survival.8-10,13 Maximal safe resection for tumor debulking
reduces tumor burden and optimizes the effectiveness of adjuvant
radiotherapy and chemotherapy.12,13
Such multimodal therapy for malignant gliomas, however, carries
a cost, and the established benefits so far are modest. In the age of
increasing economic restraints imposed on the medical system, the
value of therapies is more frequently being questioned. This also
pertains to neurosurgical interventions. For neurosurgeons, costly
adjuncts to surgery of malignant gliomas, aimed at increasing the
extent of resection, are intraoperative magnetic resonance imaging
and 5-aminolevulinic acid (5-ALA; Gliolan). For both adjuncts, the
cost-effectiveness is difficult to fathom. With this analysis, we have
attempted to demonstrate the feasibility of cost-effectiveness analyses
for neurosurgical procedures, using 5-ALA as an example.
5-ALA is an orally administered prodrug used for visualization of
high-grade glioma tissue during surgery, allowing a safer and more
extensive tumor resection. 5-ALA is metabolized to protoporphyrin
IX, a precursor of heme. High-grade glioma cells accumulate higher
amounts of protoporphyrin IX than healthy tissue. Under blue
excitation light (l = 400-410 nm), the tumor tissue appears red,
whereas normal tissue shows no fluorescence. Clinical trial data
comparing 5-ALA fluorescence-guided surgery with conventional
white-light surgery showed a significant increase in the proportion of
patients with complete resection and in 6-month progression-free
survival.8,14 These results led to the European Union approval of
5-ALA, as an orphan drug, in the indication of high-grade glioma
(World Health Organization grade III/IV).
Apart from a recent Spanish cost-effectiveness study,15 information
on cost-effectiveness of 5-ALA fluorescence-guided neurosurgery is
still scarce. Thus, we conducted a cost-effectiveness analysis of 5-ALA
fluorescence-guided neurosurgery compared with white-light neuro-
surgery in adult patients with newly diagnosed high-grade glioma
within the context of the Portuguese National Health Service.
Incremental cost-effectiveness ratios (ICERs) were estimated, con-
sidering the outcomes of quality-adjusted life-years (QALY), life-
years (LYs), and progression-free life-years (PFLYs).
METHODS
The target population of our study comprises adult patients with newly
diagnosed high-grade glioma (World Health Organization grade III/IV)
eligible for surgical resection and adjuvant therapy, treated in a Portuguese
National Health Service hospital setting according to standard clinical
practice. We also conducted subgroup analyses according to age (#55 vs
.55 years of age) and tumor location (eloquent vs noneloquent), important
TABLE 2. Resource Use and Unit Costs (2012)a
Resource Use Unit Cost, €
Gliolan 30 mg/mL for oral solutionb 1000.00
Neurosurgery19
Craniotomy .17 y without complications 4563.66
Craniotomy .17 y with complications 7087.15
Stereotaxic radiosurgery 8097.89
Radiotherapy19
Cost per session 256.49
Outpatient visits20
Cost per outpatient visit to the hospital 31.00
Home-care visits20
Cost per home-care visit 42.00
Brain imaging assessments19
Gadolinium-enhanced MRI 298.50
Contrast CT scan 136.90
Laboratory assessments19
Complete blood count 6.40
Clinical chemistryc 14.30










Hospitalization (total cost of hospitalization)19
Hematologic toxicity 1180.63
Infection 1072.56
Rash and other dermatologic toxicity 715.28
Thromboembolic events 2985.97
Pulmonary embolism 2369.89
Palliative care, malignant disease (end of life) 1230.23
Medication used for symptom management
Dexamethasone tablet, 8 mg21 1.50
Acetaminophen tablet, 1000 mg22 0.03
Metamizol magnesium capsule, 575 mg22 0.05
Fentanyl transdermal patch, 0.05 mg21 1.72
Morphine injection, 10 mg/mL21 4.06
Levetiracetam tablet, 1000 mg22 0.82
Valproic acid prolonged-released granules, 1000 mg22 0.55
Metoclopramide tablet, 10 mg22 0.02
Ondansetron tablet, 8 mg22 0.83
Cotrimoxazole tablet, 960 mg22 0.15
Amoxicillin 1 clavulanic acid tablet, 1000 mg22 0.32
Azithromycin tablet, 500 mg22 1.35
Enoxaparin, 40 mg/0.4 mL22 3.17
aCT, computed tomography; MRI, magnetic resonance imaging.
bmedac Portugal.
cClinical chemistry: alanine aminotransferase, aspartate aminotransferase,
g-glutamyltransferase, urea, glycemia, creatinine, C-reactive protein, and ionogram.
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prognostic factors. The study perspective was the Portuguese Health Care
System. Only direct medical care costs were considered, including the cost of
the intervention itself and follow-up medical care until death.
We constructed aMarkovmodel based on themodel described byGarside
et al16 and Rogers et al.17 This modeling approach allows simulation of the
natural history of disease, deterioration of the patient’s clinical condition,
and subsequent fluctuations in health-related quality of life.
The model was run as a cohort simulation of 1000 people with 1
treatment cohort (5-ALA fluorescence-guided surgery) and 1 comparator
cohort (white-light surgery), both followed by adjuvant radiochemother-
apy with temozolomide or radiotherapy. A cycle length of 1 week was
considered. The model was run until the death of all patients in both
cohorts (time horizon, 411 weeks/7.9 years), thus accounting for lifetime
costs and clinical benefits. Health outcomes were evaluated in QALYs,
LYs, and PFLYs. A discount rate of 5% was applied to both health
outcomes and costs, as recommended by the Portuguese guidelines for
pharmacoeconomic analysis.18
Model Structure
The model comprises 5 health states: surgery, stable disease with
complete resection, stable disease with partial resection, progressive
disease, and death (Figure 1). The initial state, surgery, comprises
surgery and postoperative recovery. All patients remain in this state for
a fixed period of 4 weeks; they leave only if they die. After this period, all
patients alive move to one of the stable disease states (with or without
complete resection). Both stable disease states comprise 3 sequential
substates, namely radiotherapy with or without concomitant temozolo-
mide (maximum, 6 weeks), adjuvant temozolomide (maximum, 24
weeks), and no treatment. Patients remain in stable disease states until
they either die or have disease progression. The progressive disease state
was modeled as a sequence of 120 substates to simulate subsequent
treatments and the patient’s clinical deterioration. Thus, several periods
were considered: week 1, during which a proportion of patients are
submitted to second standard white-light surgery in both cohorts (5-ALA
not considered in reoperation); weeks 2 to 52, the period that accounts for
active treatment such as chemotherapy and radiotherapy in a proportion
of patients; and weeks$53, the period accounting for supportive care. In
the progressive disease state, the patient’s clinical deterioration was
modeled assuming a 0.5% decrement of utility value per week/cycle. The
death state includes all causes of deaths.
Input Values and Study Parameters
Input parameters comprising transition probabilities, health state utilities,
and their respective sources are summarized in Table 1. Utility values were
taken from the literature. The same utility values were considered for
complete resection and partial resection stable disease states.
TABLE 3. Summary of Costs Used in the Economic Model (2012)a
Description Cohort Cost, € Details
Surgery (4 wk) 5-ALA, white-light 5816.01, 4816.01 Total cost of surgery and postoperative period (4 wk); MRI as part of surgical
workup; cost of Gliolan in the 5-ALA cohort; inpatient day in high-





Both 1356.15/wk Cost of radiotherapy, TMZ, antiemetics and Pneumocystis jirovecci prophylaxis;
outpatient visits; laboratory and imaging assessments; grade 3/4 toxicity
affecting .1% of patients (inpatient costs); concomitant treatment for




Both 95.51/wk Cost of TMZ; outpatient visits; laboratory and imaging assessments; grade 3/4
toxicity affecting.1% of patients (inpatient costs); concomitant treatment for
symptom managementb
No active treatment Both 32.02/wk Outpatient visits; imaging assessments; concomitant treatment for symptom
managementb
Progressive disease
First week Both 1282.77 To reflect reoperation (28% of patients)
Week 2-52 Both 169.04/wk To reflect active treatment with chemotherapy and/or radiotherapy (70% of
patients); outpatient visits; laboratory and imaging assessments; concomitant
treatment for symptom managementb
Subsequent weeks Both 62.52/wk Outpatient visits; laboratory and imaging assessments; concomitant treatment
for symptom managementb
Palliative care Both 1055.02 (one-off cost
applied on death)
End-of-life hospitalizations and home care; concomitant treatment for end-of-
life symptom reliefc
a5-ALA, 5-aminolevulinic acid; MRI, magnetic resonance imaging; RT6 TMZ, radiotherapy with or without concomitant temozolomide; TMZ, temozolomide; TMZadj, adjuvant
temozolomide.
bAntiepileptics, corticosteroids, antiemetics, analgesics, and anticoagulation therapy.
cAntiepileptics, corticosteroids, antiemetics, analgesics, anticoagulation therapy, and anti-infective drugs.
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An expert panel (composed of 1 radio-oncologist, 2 neuro-oncologists,
and 1 neurosurgeon) validated the Portuguese clinical practice and
resource use from diagnosis until death.
The panel defined the fixed transition probability from surgery to
death. Transition probabilities from surgery to stable disease states (with
or without complete resection) were taken from Stummer et al14
randomized clinical trial, which included 270 newly diagnosed patients
with a median age of approximately 59 years (range, 23-73 years) and
World Health Organization grade IV glioma in 97%. In this trial, 65%
of patients (90 of 139) treated with 5-ALA and 36% of patients (47 of
131) submitted to white-light surgery had a complete resection
of contrast-enhancing tumor. Only a small proportion of patients in
this trial received adjuvant chemotherapy. Because the current
standard practice comprises adjuvant radiochemotherapy with
temozolomide (the Stupp regimen), the transition probabilities from
stable disease states to death and progressive disease were based on
data from a multicenter, prospective, noninterventional cohort
study.13 This study was designed to test the effect of extensive
cytoreductive surgery when combined with temozolomide radio-
chemotherapy followed by adjuvant temozolomide on progression-
free survival and overall survival. It included 143 patients with newly
diagnosed glioblastoma eligible for surgery with a median age of 59.5
years (range, 21-81 years).13
Transition probabilities from stable disease states to death and
progressive disease states were estimated by use of parametric survival
models fitted to individual patient data from this noninterventional study.
Transition probabilities to death were estimated from a Weibull survival
modelwith a shape parameter.1, taking extent of resection as a covariate
(complete vs partial). Thus, we considered a time-dependent probability
of death that increases with time.
An exponential model, also including extent of resection as a covariate,
was used to estimate transition probabilities from stable disease states to
progressive disease. Goodness of fit of parametric models was evaluated by
comparing with Kaplan-Meier estimates (survival curves and median
survival estimates) and checking the proportionality of cumulative hazard
risk function.
The type and quantification of resources used were derived from the
expert panel. Unit costs were taken from official Portuguese reimburse-
ment lists (2012 values). Table 2 summarizes the resources and respective
unit costs considered in the model. Table 3 summarizes the costs
associated with each Markov state. Palliative care costs were attached to
the transition from progressive disease to death.
Five-ALA toxicity was not considered because clinical trial data did
not show any significant difference between fluorescence-guided
and white-light neurosurgery in the frequency of severe adverse events,
neurological impairments, or laboratory measurements with the
exception of a transient increase, without major clinical impact, of
g-glutamyl transpeptidase and alanine and aspartate transaminases.14
Grade $3 toxicities of adjuvant treatment affecting .1% of patients
were included because of the potential impact on resource use. These
comprised hematologic toxicity, severe infection, pulmonary embo-
lism, and deep vein thrombosis5 (validated by the expert panel).
Sensitivity Analysis
Extensive 1-way and probabilistic sensitivity analyses were performed.
We also evaluated the robustness of results to different discount rates (0%,
3%, 5%, and 7%).
One-way sensitivity analysis comprised the transition probabilities,
costs of each health state, and utility values. Variation limits used were the
95% confidence interval limits for the proportion of complete resections
and utilities and a 20% variation for all other parameters.
Probability distributions used in probabilistic analysis were b distri-
bution for transition probabilities and utilities, g distribution for costs,
and log normal for the parameters of survival models (Table 1).
Simultaneous multivariate stochastic analysis was performed running
1000 Monte Carlo simulations.
TABLE 4. Incremental Cost-Effectiveness Resultsa
Effectiveness and cost indicators 5-ALA White-Light Difference
Progression-free life-year 1.10 0.93 0.17
Life-year 1.90 1.68 0.22
Quality-adjusted life-year 1.36 1.20 0.16
Total cost (National Health Service perspective), € 22 516.61 21 028.64 1487.97
Incremental cost-effectiveness results (deterministic results), € ICER
Cost per progression-free life-year gained 8780.84
Cost per life-year gained 6675.52
Cost per quality-adjusted life-year gained 9097.47
Incremental cost-effectiveness results (probabilistic results), €
Lower-Limit 95%
Credibility Interval ICER Mean Value
Upper-Limit 95%
Credibility Interval
Cost per progression-free life-year gained 5025.15 9841.86 17 578.34
Cost per life-year gained 4995.59 7385.54 12 631.37
Cost per quality-adjusted life-year gained 8282.90 12 932.92 21 314.63
a5-ALA, 5-aminolevulinic acid; ICER, incremental cost-effectiveness ratio.
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An alternative scenario analysis was also conducted by use of the
Kaplan-Meier estimates with survival extrapolation with parametric
survival models from the point where insufficient data were available.
RESULTS
Base-Case Analysis
Base-case cost-effectiveness results are displayed in Table 4. The
mean effectiveness results of 5-ALA surgery projected by the model
are 1.36 QALYs, 1.10 PFLYs, and a life expectancy of 1.90 years.
These represent an increase of 0.16 QALY, 0.22 LY, and 0.17 PFLY
over white-light surgery. The results obtained show a beneficial effect
of 5-ALA in all evaluated health effects with an incremental cost of
approximately €1500 for National Health Service.
ICERs are below €10000 in all evaluated outcomes (Table 4).
Uncertainty Analysis
One-way sensitivity analyses are displayed in tornado
diagrams (Figure 2A-2C). The results concerning incremental
cost per additional QALY (Figure 2A) show that the model is
FIGURE 2. Tornado diagrams of 1-way sensitivity analyses concerning incremental cost-effectiveness ratios, National Health Service perspective. A, incremental cost per
quality-adjusted life-year gained (in euros). B, incremental cost per life-year gained (in euros). C, incremental cost per progression-free life-year gained (in euros). PDeathCR,
probability of death for patients with complete resection; PDeathPR, probability of death in patients with partial resection; Progressive .W52, progressive disease state after
week 52; ProgressiveW1, first week in progressive disease state; ProgressiveW2-W52, progressive disease state from week 2 to 52; StableNoTherapy, stable disease after partial or
complete resection without active treatment; StableRT, stable disease after partial or complete resection receiving radiotherapy; StableTMZadj, stable disease after partial or
complete resection receiving adjuvant temozolomide treatment; StableTMZcRT, stable disease after partial or complete resection receiving concomitant radiotherapy and
temozolomide; StaCR2Pro, probability of progression in patients with complete resection; StaPR2Pro, probability of progression in patients with partial resection;
Surg2CRGliolan, probability of complete resection with 5-aminolevulinic acid surgery.
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particularly sensitive to changes in the utility value attributed
to the stable disease with no therapy substate. The other 3
most influential variables are the proportion of patients with
complete resection in the 5-ALA cohort and the 2 transition
probabilities from stable disease states (with complete and
partial resection) to progressive disease. In all plausible
variations tested, incremental cost per additional QALY is
below €14000 (Figure 2A).
The parameters with the greatest impact in incremental cost per
additional LY (Figure 2B) and per additional PFLY (Figure 2C)
are the proportion of patients with complete resection in the
5-ALA cohort, the probabilities of death in patients with
complete and partial remission, and the probability of progression
from stable disease states. It should be noted that all plausible
variations tested yield incremental costs per LY gained and
incremental costs per PFLY gained below €9000 and €12000,
respectively (Figure 2B and 2C).
Results are robust to variation in discount rates (0%, 3%, 5%,
and 7%), ranging from€8250 to €10127 for incremental cost per
additional QALY, €5963 to €7473 for incremental cost per
additional LY, and €8174 to €9678 for incremental cost per
additional PFLY.
FIGURE 3. Scatter diagram of Monte Carlo simulation results in the cost-effectiveness plane, National Health Service per-
spective. A, incremental cost per quality-adjusted life-year (QALY) gained. B, incremental cost per life-year (LY) gained. C,
incremental cost per progression-free life-year (PFLY) gained. The gray line represents a willingness-to-pay threshold of €20000
per additional QALY, LY, or PFLY. Results are located in the upper-right quadrant, reflecting a beneficial effect of 5-
aminolevulinic acid fluorescence-guided surgery in all health effects evaluated but at a higher cost. In the 3 scatterplots, the
majority of the simulation results are located below the threshold line, indicating a very high probability of incremental cost-
effectiveness ratio being inferior to €20000 for all health effects evaluated.
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Probabilistic analysis results are given in Table 4. These show
that, in 95% of cases, incremental cost per LY gained and
incremental cost per PFLY gained are inferior to €13000 and
€18000, respectively. When the ICER for QALY is considered,
the upper limit of the 95% credibility interval increases to
€21000, which might be explained by the poor underlying
quality of life usually reported in these patients.
In Figure 3A through 3C, the ICER results of 1000 Monte
Carlo simulations for the 3 health outcomes are graphically
presented on the cost-effectiveness plane. It can be clearly seen
that the overwhelming majority of simulation results are located
in the upper-right quadrant below the willingness-to-pay
threshold of €20000. This reflects a beneficial effect of 5-
ALA surgery compared with white-light surgery and suggests
a high probability of an additional cost below €20000 in all
health effects evaluated. This is further confirmed by the cost-
effectiveness acceptability curves (Figure 4A-4C), which show
the probability of considering 5-ALA cost-effective at different
willingness-to-pay thresholds, given joint parameter uncer-
tainty. The probability of 5-ALA cost-effectiveness at a threshold
of €20000 is 99.6% for LY, 98.8% for PFLY, and 96.0% for
QALY.
ICER point estimates obtained in alternative scenario analysis
using Kaplan-Meier estimates are €8868.92 per PFLY gained,
€6820.88 per LY gained, and €9401.99 per additional QALY.
These results are similar to those obtained in the base-case
analyses with parametric survival models (Table 4).
Subgroup Analyses
Table 5 presents the ICER point estimates obtained in
subgroup analyses. These results are similar to those of the base
case but suggest that 5-ALA is more cost-effective in patients,56
years of age and with eloquent tumor location for all end points.
DISCUSSION
We performed a cost-effectiveness analysis of 5-ALA surgery
compared with white-light surgery, current standard practice in
Portuguese hospitals, in newly diagnosed adult patients with high-
grade glioma.
FIGURE 4. Cost-effectiveness acceptability curves, National Health Service perspective. A, incremental cost-per quality adjusted
life-year gained. B, incremental cost per life-year gained. C, incremental cost per progression-free life-year gained. The
acceptability curves represent, for several willingness-to-pay threshold values ranging from €0 to €50000, the probability that the
incremental cost-effectiveness ratio is below the considered threshold value. 5-ALA, 5-aminolevulinic acid.
5-ALA COST-EFFECTIVENESS IN HIGH-GRADE GLIOMA
NEUROSURGERY VOLUME 76 | NUMBER 5 | MAY 2015 | 559
Copyright © Congress of Neurological Surgeons. Unauthorized reproduction of this article is prohibited.
A similar analysis might be performed for other adjuncts to glioma
surgery, provided that the effects on resection are well characterized,
such as for intraoperative magnetic resonance imaging.23
The study perspective adopted was the Portuguese National
Health Service. ICERs for the 3 health outcomes evaluated (QALY,
LY, andPFLY) are between€6600 and €9300. These values are well
below the willingness-to-pay threshold of £20000 considered by
National Institute of Clinical Excellence.24 Extensive 1-way and
probabilistic sensitivity analyses showed robustness of the results to
uncertainties in model parameter estimates. Although subgroup
analysis results are similar to the results of the base case, they suggest
a higher cost-effectiveness of 5-ALA in patients,56 years of age and
with eloquent tumor location.
Limitations
One important assumption of our Markov model is the
separation of stable disease states on the basis of complete and
partial resection. Although this may be regarded as an over-
simplification, it is grounded by several studies showing that
complete resection is an independent prognostic factor for overall
survival.8-10,13 Another assumption is the time-dependent,
instead of state-dependent, risk of death, which appears to be
a counterintuitive approach because probability of death is
expected to be higher in progressive states. However, transition to
death was based on a Weibull model in which the probability of
death increases with time as more patients also experience disease
progression. A third assumption is that all patients receive surgery
soon after diagnosis and postoperative treatment shortly after
surgery. The potential impact of longer waiting times was not
considered.
Our model was based on clinical data from 2 studies, 1 head-to-
head randomized clinical trial comparing 5-ALA surgery with
white-light surgery14 and 1 noninterventional prospective cohort
study designed to test the effect of extensive cytoreductive surgery
combined with the Stupp regimen.5,13 As a consequence, our
study has a limitation related to data availability that renders
model estimations dependent on any bias in these studies such as
the underrepresentation of grade III gliomas. In addition, there is
some degree of uncertainty in survival estimation resulting from
small sample size and limited follow-up (median, 24 months).
Nevertheless, the goodness of fit of the parametric survival
models was acceptable for both the Weibull and exponential
models. Finally, the probabilistic sensitivity analysis and the
Kaplan-Meyer alternative scenario showed that results are robust
to the variability of the parameters of the survival models.
It is likely, however, that the present analysis underestimates
the cost-effectiveness of 5-ALA. The assumptions for the
incremental rates of resections when 5-ALA is used were taken
from the approval study published in 200614 and thus were
based on the first patients operated on. To date, the
experience with 5-ALA has increased, and the use of
neurophysiological monitoring has become much more
common for high-grade gliomas. Published resection rates
are now between 80% and 96%.25-27
To the best of our knowledge, the most relevant clinical studies
published to date that evaluated the impact of extent of resection in
survival did not include adjuvant radiochemotherapy with temozo-
lomide as part of treatment.7-9,28 The observational, retrospective
study of the effectiveness of 5-ALA in malignant glioma in Spain
(the VISIONA study)29 included this therapy but reported only
results concerning complete resection rate and 6-month progression-
free survival. For these reasons, it is not possible to make direct
comparisons of survival outcomes between VISIONA and the
noninterventional study used in our model.
Another aspect to be considered is the use of utility values
obtained from a panel of British respondents, which do not ne-
cessarily match the preferences of the Portuguese population.
The pharmacoeconomic study published by Slof et al,15 based
on data collected in the VISIONA observational study,29 also
compared 5-ALA surgery with white-light surgery in newly
diagnosed adult patients undergoing surgery for malignant
glioma. Despite comparing the gains in QALYs between
treatment groups, the Slof et al15 study included only the
incremental costs associated with the 5-ALA intervention,
which are incurred in the beginning of the analysis period.
This is an important difference from our model; we considered
not only the costs of initial surgery but also the costs incurred
after surgery, during the lifetime of all patients. Interestingly,
the results of incremental cost per additional QALY are similar
in both studies. This may be explained in part by the minor gain
in QALYs considered in the Slof et al15 study, together with an
underestimation of the incremental costs.
Our model did not evaluate the potential effect of 5-ALA
surgery at recurrence. Given that the extent of resection has
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been shown to be an important prognostic factor not only in
initial resection but also at recurrence,30 this question should
be addressed in future studies. In addition, future studies
should also include subgroup analysis comprising important
prognostic factors such as the methylation status of the O6-
methylguanine-DNA methyltransferase promoter. Given the
synergistic effect between complete resection and adjuvant
radiochemotherapy particularly seen in patients with O6-
methylguanine-DNA methyltransferase promoter methyla-
tion,13 a higher cost-effectiveness of 5-ALA may be antici-
pated in this subgroup.
Finally, future studies should also consider a societal perspec-
tive, taking into account productivity losses, family costs, and
other indirect and direct nonmedical costs incurred by the
patient.
CONCLUSION
Our analysis suggests that 5-ALA fluorescence-guided surgery is
cost-effective in newly diagnosed high-grade gliomas compared
with white-light surgery.
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P roperly performed cost-effectiveness studies are essential to societiesthat seek to pool and intelligently use limited healthcare resources.
Modeling studies such as this one are central to that process; however, the
results of such studies are only as reliable as the hard data and assumptions
from which a given model is created. Here, each of the 2 critical inputs
(1, that the rate of achieving gross total resection is significantly greater
when using 5-aminolevulinic acid [5-ALA] than when performing stan-
dard white-light resection; and 2, that radiographic gross total resection
increases longevity without increasing neurological complications) is
based either on just 1 study (item 1), or studies that are contradicted by
others (item 2). Even if both of these inputs are true, the model demon-
strates that use of 5-ALA yields amodest increase in quality survival of 0.16
quality-adjusted life-year, or 8.3 weeks. For an intervention yielding such
a modest extension of life to be cost-effective, it must be quite inexpensive
relative to the overall cost of therapy, which at €1500, 5-ALA is. To me,
the question is not whether 5-ALA–guided glioblastoma resection is cost-
effective but whether it truly confers a significant increase in quality
survival. If it does, the modest additional cost of using it will not be an
issue. Conversely, given the modest quality-adjusted life-year gains
predicted by the model, a prospective randomized trial comparing real-
world outcomes in patients operated on with and without 5-ALA
guidance will require a very large cohort to detect a statistically significant
extension of meaningful survival. Such a study would be quite expensive
to conduct and so seems impractical.
Ron L. Alterman
Boston, Massachusetts
M odeling techniques as used in this study are rapidly becoming usefulfor providing insight into various disease processes and assessments
of treatment. Their use here may be indicative and at this stage in the
appraisal of use of the 5-aminolevulinic acid (5-ALA) technique is inter-
esting, although the article is based largely on glioblastoma 5-ALA studies
that show optimistic data. Caution is necessary in that modeling can be
whatever the authors wish it to be, and frequently there is a great deal of
bias in this sort of work. However, as long as various input parameters are
included to demonstrate various outcomes, the reader will benefit from
such information that may reflect scenarios of surgical improvement,
effectiveness, and economic advantage. The studies showing the benefit of
5-ALA over standard white-light operativemicroscopy should be balanced
with data taken from other studies and then used as part of the model.
Such modeling should be updated as new data or parameters become
available for input or mathematical techniques are refined.
I suspect the authors are onto something and believe that, as they do,
there are other ways that might be better at identifying the regions of
tumor cells than conventional magnetic resonance imaging, which at-
tempts to assess the tumor margins on the basis of contrast enhancement
or anatomic boundaries, and that this obviously influences survival and
economics. The point is, How much does the 5-ALA method influence
medical economics and survival? 5-ALA and other fluorescent labeling
techniques, combined with new imaging technology, may better iden-
tify the tumor cellular mass and individual migrating cells in vivo, which
must be the goal for more complete resection. Similarly, other imaging
technologies such as 1H-magnetic resonance spectroscopic imaging
have been able to show the metabolic and chemical changes that precede
structural change or progression in glioblastoma, but unfortunately,
such technology has not taken hold or been subjected to rigorous
cost-effective analysis, although in certain neurosurgical centers it has
been of advantageous use.
The point is that we can do better than basing resections on imaging
technology that we believe indicates or reflects the tumor mass or
margins when it does not. Although the actual gains noted in this study
for survival are minimal, perhaps they are a step forward in accom-
plishing better glioblastoma resection, which, along with the topic of
survival, has been the subject of the same discussions since the 1920s and
with which we have had little success in real, meaningful improvement
in survival or quality of life. If we significantly improve survival, then
there should be an economic benefit, provided that the benefit is also
better quality of life, not just more tumor resected from the brain. This
study seems to indicate an economic benefit for the PortugueseNational
Health System and, if representative, should have greater impact in
a health system that entails greater patient care expenses. However, the
limited nature of this study will need to be further explored with addi-
tional modeling, but crucial answers to these issues will require studies of
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